



CASE D0051 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico
Type or print name

Signature

Date

10-27-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1646

CHEN ET AL.

Examiner: MOORE, WILLIAM W

APPLICATION NO: 09/993,180

FILED: NOVEMBER 14, 2001

FOR: POLYNUCLEOTIDE ENCODING A NOVEL HUMAN SERPIN
SECRETED FROM LYMPHOID CELLS LSI-01

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289
Date: 10-27-04

Signature
Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652



CASE D0051 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico
Type or print name


Signature

10-27-04
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1646

CHEN ET AL.

Examiner: MOORE, WILLIAM W

APPLICATION NO: 09/993,180

FILED: NOVEMBER 14, 2001

FOR: POLYNUCLEOTIDE ENCODING A NOVEL HUMAN SERPIN
SECRETED FROM LYMPHOID CELLS LSI-01

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.


11/01/2004 RECORDED 00000002 193860 03393100

01 FC:1005 100.00 32

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289



Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: 10-27-04

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

D0051 NP

APPLICATION NO.

09/993,180

APPLICANT

CHEN ET AL.

FILING DATE

NOVEMBER 14, 2001

Group

1646



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO0155390A1	8/2/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO0214358A2	2/21/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO02072769AW	9/19/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO9811134	3/19/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO0200690A2	1/3/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Altschul, et al., "Basic Alignment Search Tool", J. Mol. Biol, Vol. 215, pp. 403-410 (1990)
	AS	Backes, et al., "Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin", Nature Biotechnology, Vol. 18, pp. 187-193 (2000)
	AT	Balasubramanian, et al., "Active Site-Directed Synthetic Thrombin Inhibitors: Synthesis, in Vitro and in Vivo Activity Profile of BMV 44621 and Analogs. An Examination of the Role of the Amino Group in the D-Phe-Pro-Arg-H Series", J. Med. Chem., Vol. 36, pp. 300-303 (1993)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.

D0051 NP

APPLICATION NO.


09/993,180

APPLICANT

CHEN ET AL.

FILING DATE

NOVEMBER 14, 2001

Group
1646**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	TRANSLATION	
							YES	NO
	2AA	WO0208284A2	1/31/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AB						<input type="checkbox"/>	<input type="checkbox"/>
	AC						<input type="checkbox"/>	<input type="checkbox"/>
	AD						<input type="checkbox"/>	<input type="checkbox"/>
	AE						<input type="checkbox"/>	<input type="checkbox"/>
	AF						<input type="checkbox"/>	<input type="checkbox"/>
	AG						<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>
	AI						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>
	AK						<input type="checkbox"/>	<input type="checkbox"/>
	AL						<input type="checkbox"/>	<input type="checkbox"/>
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>
	AR						<input type="checkbox"/>	<input type="checkbox"/>
	AS						<input type="checkbox"/>	<input type="checkbox"/>
	AT						<input type="checkbox"/>	<input type="checkbox"/>
	AU						<input type="checkbox"/>	<input type="checkbox"/>
	AV						<input type="checkbox"/>	<input type="checkbox"/>
	AW						<input type="checkbox"/>	<input type="checkbox"/>
	AX						<input type="checkbox"/>	<input type="checkbox"/>
	AY						<input type="checkbox"/>	<input type="checkbox"/>
	AZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0051 NP
APPLICATION NO.
09/993,180
APPLICANT
CHEN ET AL.
FILING DATE
NOVEMBER 14, 2001Group
1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

3AA	Bateman, et al., "The Pfam Protein Families Database", Nucleic Acids Research, Vol. 28(1), pp. 263-266 (2000)
3AB	Baumann, et al., "Crystal Structure of Cleaved Human α_1 - Antichymotrypsin at 2.7 Å Resolution and Its Comparison with Other Serpins", J. Mol. Biol., Vol. 218, pp. 595-606 (1991)
3AC	Blinder, et al., "Site-directed Mutagenesis of Arginine 103 and Lysine 185 in the Proposed Glycosaminoglycan-binding Site of Heparin Cofactor II", J. Biol. Chem., Vol. 265(1), pp. 286-291 (1990)
3AD	Blinder, et al., "Heparin Cofactor II _{Oslo} , Mutation of ARG-189 To His Decreases The Affinity for Dermatan Sulfate", J. Biol. Chem., Vol. 264(9), pp. 5128-5133 (1989)
3AE	Bohm, Hans-Joachim, "The computer program LUDI: A new method for the de novo design of enzyme inhibitors", J. Computer-Aided Molecular Design, Vol. 6, pp. 61-78 (1992)
3AF	Cajot, et al., "Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells", PNAS, Vol. 87, pp. 6939-6943 (1990)
3AG	Cardozo, et al., "Homology Modeling by the ICM Method", Proteins, Vol. 23, pp. 403-414 (1995)
3AH	Carrell, et al., "The Serpins: Evolution and Adaptation in a Family of Protease Inhibitors", Cold Spring Harbor Symposia on Quantitative Biology", Vol. LII, pp. 527-535 (1987)
3AI	Carrell, et al., " α_1 - Antitrypsin and the serpins: variation and countervariation", TIBS, pp. 20-24 (1985)
3AJ	Chai, et al., "Molecular Cloning, Sequence Analysis, and Chromosomal Localization of the Human Protease Inhibitor 4 (Kallistatin) Gene (P14)", Genomics, Vol. 23, pp. 370-378 (1994)
3AK	Chai, et al., "Kallistatin: A Novel Human Serine Proteinase Inhibitor", J. Biol. Chem., Vol. 268 (32), pp. 24498-24505 (1993)
3AL	Chandra, et al., "Sequence Homology between Human " α_1 - Antichymotrypsin, α_1 -Antitrypsin, and Antithrombin III", Biochem., Vol. 22(22), pp. 5055-5061 (1983)
3AM	Chen, Wen-Tien, "Membrane proteases: roles in tissue remodeling and tumour invasion", Curr. Opin. Cell Biol., Vol. 4, pp. 802-809 (1992)
3AN	Clarke, et al., "Cloning of a human collagen-binding protein, and its homology with rat gp46, chick hsp47 and mouse J6 proteins", Biochimica Biophysica Acta, Vol. 1129, pp. 246-248 (1992)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0051 NP
APPLICATION NO.
09/993,180
APPLICANT
CHEN ET AL.
FILING DATE
NOVEMBER 14, 2001Group
1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

4AA	Clark, et al., "The Secreted Protein Discovery Initiative (SPDI), a Large-Scale Effort to Identify Novel Human Secreted and Transmembrane Proteins: A Bioinformatics Assessment", Genome Res., Vol. 13, pp. 2265-2270 (2003)
4AB	Combrink, et al., "1,2-Benzisothiazol-3-one 1,1-Dioxide Inhibitors of Human Mast Cell Tryptase", J. Med. Chem., Vol. 41, pp. 4854-4860 (1998)
4AC	Cooper, et al., "Phosphorylation Sites in Enolase and Lactate Dehydrogenase Utilized by Tyrosine Protein Kinases in Vivo and in Vitro", J. Biol. Chem., Vol. 259(12), pp. 7835-7841 (1984)
4AD	Dano, et al., "Plasminogen Activators, Tissue Degradation, and Cancer", Advances in Cancer Research, Vol. 44, pp. 139-266 (1985)
4AE	Feramisco, et al., "Optimal Spatial Requirements for the Location of Basic Residues in Peptide Substrates for the Cyclic AMP-dependent Protein Kinase", J. Biol. Chem., Vol. 255(9), pp. 4240-4245 (1980)
4AF	Foekens, et al., "Prognostic Value of Urokinase-type Plasminogen Activator in 671 Primary Breast Cancer Patients", Cancer Res., Vol. 52, pp. 6101-6105 (1992)
4AG	Flink, et al., "Complete amino acid sequence of human thyroxine-binding globulin deduced from cloned DNA: Close homology to the serine antiproteases", PNAC, Vol. 83, pp. 708-7712 (1986)
4AH	Forgue-Lafitte, "Effects of Ketoconazole on the Proliferation and Cell Cycle of Human Cancer Cell Lines", Cancer Res., pp. 6827-6831 (1992)
4AI	Foucre', et al., "Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs. benign breast tumours", Br. J. Cancer, Vol. 64, pp. 926-932 (1991)
4AJ	Gils, et al., "Structure-function Relationships in Serpins: Current Concepts and Controversies", Thromb. Haemost., Vol. 80, pp. 531-541 (1998)
4AK	Glass, et al., "Phosphorylation by Cyclic GMP-dependent Protein Kinase of a Synthetic Peptide Corresponding to the Autophosphorylation Site in the Enzyme", J. Biol. Chem., Vol. 258(24), pp. 14797-14803 (1983)
4AL	Glass, et al., "Synthetic Peptides Corresponding to the Site Phosphorylated in 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase as Substrates of Cyclic Nucleotide-dependent Protein Kinases", J. Biol. Chem., Vol. 261(6), pp. 2987-2993 (1986)
4AM	Goodford, P.J., "A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules", J. Med. Chem., Vol. 28, pp. 849-857 (1985)
4AN	Goodsell, et al., "Automated Docketing of Substrates to Proteins by Simulated Annealing", Proteins, Vol. 8, pp. 195-202 (1990)


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0051 NP
APPLICATION NO.
09/993,180
APPLICANT
CHEN ET AL.
FILING DATE
NOVEMBER 14, 2001Group
1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

5AA	Grand, Roger, J.A., "Acylation of viral and eukaryotic proteins", Biochem. J., Vol. 258, pp. 625-638 (1989)
5AB	Heidtmann, et al., "Synthesis and Secretion of Plasminogen Activators and Plasminogen Activator Inhibitors in Cell Lines of Different Groups of Human Lung Tumors", Cancer Res., Vol. 49, pp. 6960-6965 (1989)
5AC	Hendlich, et al., "Identification of Native Protein Folds Amongst a Large Number of Incorrect Models", J. Mol. Biol., Vol. 216, pp. 167-180 (1990)
5AD	Hocini, et al., "Secretory Leukocyte Protease Inhibitor Inhibits Infection of Monocytes and Lymphocytes with Human Immunodeficiency Virus Type 1 but Does Not Interfere with Transcytosis of Cell-Associated Virus across Tight Epithelial Barriers", Clin. Lab. Diagnostic Lab. Immunol., Vol. 7(3), pp. 515-518 (2000)
5AE	Memorec, et al., "The Prosite Database, its Status in 1999", Nucleic Acid Res., Vol. 27(1), pp. 215-219 (1999)
5AF	Holland, et al., "A Major Estrogen-regulated Protein Secreted from the Liver of Xenopus laevis is a Member of the Serpin Superfamily", J. Biol. Chem., Vol. 267(10), pp. 7053-7059 (1992)
5AG	Huber, et al., "Implications of the Three-Dimensional Structure of α_1 -Antitrypsin for Structure and Function of Serpins", Biochem., Vol. 28(23), pp. 8951-8966 (1989)
5AH	Hunter, Tony, "Synthetic Peptide Substrates for a Tyrosine Protein Kinase", J. Biol. Chem., Vol. 257(9), pp. 4843-4848 (1982)
5AI	Huntington, et al., "Structure of a serpin-protease complex shows inhibition by deformation", Nature, Vol. 407, pp. 923-926 (2000)
5AJ	Janicke, et al., "Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer", Breast Cancer Res. Treatment, Vol. 24, pp. 195-208 (1993)
5AK	Kalaria, et al., "Molecular Aspects of Inflammatory and Immune Responses in Alzheimer's Disease", Neurobiology of Aging, Vol. 17(5), pp. 687-693 (1996)
5AL	Kam, et al., "Granzymes (lymphocyte serine proteases): characterization with natural and synthetic substrates and inhibitors", Biochimica Biophysica Acta, Vol. 1477, pp. 307-323 (2000)
5AM	Kishimoto, et al., "Studies on the Phosphorylation of Myelin Basic Protein by Protein Kinase C and Adenosine 3':5'-Monophosphate-dependent Protein Kinase", J. Biol. Chem., Vol. 260(23), pp. 12492-12499 (1985)
5AN	Komiyama, et al., "Inhibition of Interleukin-1 β Converting Enzyme by the Cowpox Virus Serpin CrmA", J. Biol. Chem., Vol. 269(30), pp. 19331-19337 (1994)

EXAMINER

DATE CONSIDERED


*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0051 NP
APPLICATION NO.
09/993,180
APPLICANT
CHEN ET AL.
FILING DATE
NOVEMBER 14, 2001

Group
1646



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

6AA	Kreil, Gunther, "Occurrence, Detection, and Biosynthesis of Carboxy-Terminal Amides", Methods Enzymology, Vol. 106, pp. 218-223 (1984)
6AB	Kuntz, et al., "A Geometric Approach to Macromolecule-Ligand Interactions", J. Mol. Biol., Vol. 161, pp. 269-288 (1982)
6AC	Lane, et al., "Antithrombin and its deficiency states", Blood Coagulation Fibrinolysis, Vol. 3, pp. 315-341 (1992)
6AD	Lindmark, et al., "The microheterogeneity of desialylated α_1 -antichymotrypsin: the occurrence of two amino-terminal isoforms, one lacking a His-Pro dipeptide", Biochimica Biophysica Acta, Vol. 997, pp. 90-95 (1989)
6AE	Lukacs, et al., "Arginine substitutions in the hinge region of antichymotrypsin affect serpin β -sheet rearrangement", Nature, Vol. 3(10), pp. 888-893 (1996)
6AF	Lukacs, et al., "Engineering an Anion-Binding Cavity in Antichymotrypsin Modulates the 'Spring-Loaded' Serpin-Protease Interaction", Biochem., Vol. 37, pp. 3297-3304 (1998)
6AG	Martin, et al., "Calphotin: A Drosophila photoreceptor cell calcium-binding protein", PNAS, Vol. 90, pp. 1531-1535 (1993)
6AH	Meissauer, et al., "Urokinase-Type and Tissue-Type Plasminogen Activators Are Essential for in Vitro Invasion of Human Melanoma Cells", Vol. 192, pp. 453-459 (1991)
6AI	Miller, Andrew, "The European Synchrotron Radiation Facility and Angiography", Curr. Op. Struct. Biol., Vol. 2, pp. 242-247 (1992)
6AJ	Ngan, et al., "Expression in Non-Hodgkin's Lymphoma of the bcl-2 Protein Associated with the t(14;18) Chromosomal Translocation", New England J. Med., Vol. 318(25), pp. 1638-1644 (1988)
6AK	Nguyen, et al., "The Specific Variable Domain of Camel Heavy-chain Antibodies is Encoded in the Germline", J. Mol. Biol., Vol. 275, pp. 413-418 (1998)
6AL	Martin, Yvonne, C., "3D Database Searching in Drug Design", J. Med. Chem., Vol. 35(12), pp. 2145-2154 (1992)
6AM	Morii, et al., "Amino Acid Sequence at the Reactive Site of Human α_1 -Antichymotrypsin", J. of Biol. Chem., Vol. 258(21), pp. 12749-12752 (1983)
6AN	Novotny, et al., "Criteria That Discriminate Between Native Proteins and Incorrectly Folded Models", Proteins, Vol. 4, pp. 19-30 (1988)

EXAMINER


DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.
D0051 NP
APPLICATION NO.
09/993,180
APPLICANT
CHEN ET AL.
FILING DATE
NOVEMBER 14, 2001

Group
1646



(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

7AA	Opal, Steven, M., "Therapeutic rationale for antithrombin III in sepsis", Crit. Care Med., Vol. 28(9), pp. S34-S37 (2000)
7AB	O'Reilly, et al., "Antiangiogenic Activity of the Cleaved Conformation of the Serpin Antithrobin", Science, Vol. 285, pp. 1926-1928 (1999)
7AC	Ossowski, Liliana, "Invasion of Connective Tissue by Human Carcinoma Cell Lines: Requirement for Urokinase, Urokinase Receptor, and Interstitial Collagenase", Cancer Res., Vol. 52, pp. 6754-6760 (1992)
7AD	Osterwalder, et al., "Neuroserpin, an axonally secreted serine protease inhibitor", EMBO J., Vol. 15(12), pp. 2944-2953 (1996)
7AE	Pan, et al., "Two Newly Characterized Germinal Center B-Cell-Associated Genes, GCET1 and GCET2, Have Differential Expression in Normal and Neoplastic B Cells", Amer. J. Path., Vol. 163(1), pp. 135-144 (2003)
7AF	Patschinsky, et al., "Analysis of the sequence of amino acids surrounding sites of tyrosine phosphorylation", PNAS, Vol. 79, pp. 973-977 (1982)
7AG	Pearson, William, R., "Rapid and Sensitive Sequence Comparison with FASTP and FASTA", Methods Enzymology, Vol. 183, pp. 63-98 (1990)
7AH	Peltier, et al., "Regulation of Lymphocyte Proliferation by Uterine Serpin: Interleukin-2 mRNA Production, CD25 Expression and Responsiveness to Interleukin-2", Vol. 223, pp. 75-81 (2000)
7AI	Pinna, Lorenzo, A., "Casein kinase 2: an 'eminence grise' in cellular regulation?", Biochimica Biophysica Acta, Vol. 1054, pp. 267-284 (1990)
7AJ	Poller, et al., "A Leucine-to-Proline Substitution Causes a Defective α^1 -Antichymotrypsin Allele Associated with Familial Obstructive Lung Disease", Genomics, Vol. 17, pp. 740-743 (1993)
7AK	Pratt, et al., "Antithrombin: Structure and Function", Seminars in Hematology, Vol. 28(1), pp. 3-9 (1991)
7AL	Ragg, et al., "Glycosaminoglycan-mediated Leuserpin-2/Thrombin Interaction", J. Biol. Chem., Vol. 265(36), pp. 22386-22391 (1990)
7AM	Reed, et al., "Synergistic fibrinolysis: Combined effects of plasminogen activators and an antibody that inhibits α_2 -antiplasmin", PNAS, Vol. 87, pp. 1114-1118 (1990)
7AN	Reilly, et al., "Type-1 Plasminogen Activator Inhibitor in Human Breast Carcinomas", Int. J. Cancer, Vol. 50, pp. 208-214 (1992)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0051 NP
APPLICATION NO.
09/993,180
APPLICANT
CHEN ET AL.
FILING DATE
NOVEMBER 14, 2001

Group
1646


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

8AA	Remold-O'Donnell, Eileen, "The ovalbumin family of serpin proteins", FEBS, Vol. 315(2), pp. 105-108 (1993)
8AB	Rubin, et al., "Cloning, Expression, Purification, and Biological Activity of Recombinant Native and Variant Human α 1-Antichymotrypsins", J. Biol. Chem., Vol. 265(2), pp. 1199-1207 (1990)
8AC	Saitou, et al., "Identification of the TCL6 genes within the breakpoint cluster region on chromosome 14q32 in T-cell leukemia", Oncogene, Vol. 19, pp. 2796-2802 (2000)
8AD	Sali, et al., "Evaluation of Comparative Protein Modeling by Modeller", Proteins, Vol. 23, pp. 318-326 (1995)
8AE	Shirasuna, et al., "Extracellular Matrix Production and Degradation by Adenoid Cystic Carcinoma Cells: Participation of Plasminogen Activator and Its Inhibitor in Matrix Degradation", Cancer Res., Vol. 53, pp. 147-152 (1993)
8AF	Shirk, et al., "Role of the H Helix in Heparin Binding to Protein C Inhibitor", J. Biol. Chem., Vol. 269(46), pp. 28690-28695 (1994)
8AG	Sumiyoshi, et al., "Plasminogen Activator System in Human Breast Cancer", Int. J. Cancer, Vol. 50, pp. 345-348 (1992)
8AH	Sumiyoshi, et al., "Increase in Levels of Plasminogen Activator and Type-1 Plasminogen Activator Inhibitor in Human Breast Cancer: Possible roles in tumor progression and metastasis", Thromb. Res., Vol. 63, pp. 59-71 (1991)
8AI	Testa, et al., "The role of urokinase-type plasminogen activator in aggressive tumor cell behavior", Cancer Metastasis Reviews, Vol. 9, pp. 353-367 (1990)
8AJ	Towler, et al., "The Biology and Enzymology of Eukaryotic Protein Acylation", Ann Rev. Biochem., Vol. 57, pp. 69-99 (1988)
8AK	Tsuda, et al., "Detection of a new mutant α -1-antichymotrypsin in patients with occlusive-cerebrovascular disease", FEBS, Vol. 304(1), pp. 66-68 (1992)
8AL	Whinna, et al., "Role of Lysine 173 in Heparin Binding to Heparin Cofactor II", J. Biol. Chem., Vol. 266(13), pp. 8129-8135 (1991)
8AM	Whisstock, et al., "An atlas of serpin conformations", TIBS, Vol. 23, pp. 63-67 (1998)
8AN	Woodgett, et al., "Substrate specificity of protein kinase C", J. Biochem., Vol. 161, pp. 177-184 (1986)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.




INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0051 NP
APPLICATION NO.
09/993,180
APPLICANT
CHEN ET AL.
FILING DATE
NOVEMBER 14, 2001

Group
1646



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

9AA	Zou, et al., "Maspin, a Serpin with Tumor-Suppressing Activity in Human Mammary Epithelial Cells", Science, Vol. 263, pp. 526-529 (1994)
9AB	NCBI Entrez Accession No. AL132708 (gi:7009592), Heilig, et al., May 4, 2001
9AC	NCBI Entrez Accession No. AL132990 (gi:15796543), Heilig, et al., September 26, 2001
9AD	NCBI Entrez Accession No. CAA45509 (gi:37142), Akbari, et al., June 26, 1997
9AE	NCBI Entrez Accession No. CAD29031 (gi:19701015), Edmonds, et al., March 23, 2002
9AF	NCBI Entrez Accession No. NM_175739 (gi:31343337), Namciu, et al., September 3, 2004
9AG	NCBI Entrez Accession No. NP_000345 (gi:4507377), Grasberger, et al., August 23, 2004
9AH	NCBI Entrez Accession No. NP_006206 (gi:5453888), Chai, et al., November 3, 2000
9AI	NCBI Entrez Accession No. NP_783866 (gi:28376637), Namciu, et al., September 3, 2004
9AJ	NCBI Entrez Accession No. P01011 (gi:112874), Chandra, et al., October 25, 2004
9AK	NCBI Entrez Accession No. 1QLPA (gi:6137432), Elliott, et al., September 10, 1999
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.